Kenneth D Jackson

Address:

904 Meadowridge Dr, Oklahoma City, OK 73110

Phone:

6189808779

VIN:

1C4NJCEB4CD719232

Make:

JEEP

Model:

COMPASS

Year:

2012

US Patent:

7309774, Dec 18, 2007

Filed:

Feb 6, 2004

Appl. No.:

10/774242

Inventors:

Patrick A. McKee - Oklahoma City OK, US
Kyung N. Lee - Oklahoma City OK, US
Kenneth W. Jackson - Edmond OK, US
Victoria J. Christiansen - Oklahoma City OK, US

Assignee:

The Board of Regents of the University of Oklahoma - Norman OK

International Classification:

A61K 35/14

US Classification:

530380, 530350

Abstract:

Human α-antiplasmin (αAP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of αAP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or αAP, and an N-terminally-shortened 452-residue “activated”-form, or αAP. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than αAPand makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of αAPto yield αAP. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE).

US Patent:

20080057491, Mar 6, 2008

Filed:

Jun 6, 2007

Appl. No.:

11/811002

Inventors:

Patrick McKee - Oklahoma City OK, US
Kyung Lee - Oklahoma City OK, US
Kenneth Jackson - Edmond OK, US
Victoria Christiansen - Oklahoma City OK, US

International Classification:

C12Q 1/00
C07K 14/00
C07K 5/00
C07K 7/06
C07K 7/08

US Classification:

435004000, 530324000, 530325000, 530326000, 530327000, 530328000, 530330000

Abstract:

The present invention is directed toward inhibitors of antiplasmin cleaving enzyme for use in various therapies related to fibrin and α-antiplasmin, and to substrates of APCE, which may be used, for example, in screening methods for identifying such inhibitors. The present invention is further directed to methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the rations of types of plasma α-antiplasmin.

US Patent:

20080118933, May 22, 2008

Filed:

Nov 20, 2007

Appl. No.:

11/986058

Inventors:

Patrick McKee - Oklahoma City OK, US
Kyung Lee - Oklahoma City OK, US
Kenneth Jackson - Edmond OK, US
Victoria Christiansen - Oklahoma City OK, US

International Classification:

G01N 33/53
C12N 9/68

US Classification:

435007100, 435217000

Abstract:

Human α-antiplasmin (αAP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of αAP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or αAPand an N-terminally-shortened 452-residue “activated”-form, or αAP. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than αAPand makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of αAPto yield αAP. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE). Novel inhibitors of circulating APCE can diminish αAP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin. Patients who are susceptible to atherosclerotic plaque formation or are susceptible to developing thrombi that compromise organ function will benefit by therapies providing such inhibitors on a long term basis.

US Patent:

20110144037, Jun 16, 2011

Filed:

Dec 15, 2010

Appl. No.:

12/969161

Inventors:

Patrick A. McKee - Oklahoma City OK, US
Kenneth W. Jackson - Edmond OK, US
Kyung N. Lee - Oklahoma City OK, US
Victoria J. Christiansen - Oklahoma City OK, US

International Classification:

A61K 38/07
C07K 5/083
C07D 233/54
C07D 209/52
C07C 229/04
C07C 229/26
C07K 5/097
C07K 5/10
C07K 5/103
C07K 5/117
C07K 7/06
A61K 38/06
A61K 38/08
A61K 31/195
A61K 31/198
A61K 31/4172
A61K 31/4035
C12N 5/071
A61P 9/10
A61P 35/00

US Classification:

514 216, 530331, 5483391, 548516, 562553, 562561, 562562, 562563, 530330, 530329, 530328, 514 219, 514 218, 514 217, 514561, 514564, 514568, 514399, 514416, 435325

Abstract:

The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma α-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.

US Patent:

20170260231, Sep 14, 2017

Filed:

May 23, 2017

Appl. No.:

15/602709

Inventors:

- Norman OK, US
Kenneth W. Jackson - Edmond OK, US
Victoria J. Christiansen - Oklahoma City OK, US

International Classification:

C07K 5/11
C07K 5/072
C07K 5/062

Abstract:

Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.

US Patent:

20170066800, Mar 9, 2017

Filed:

Nov 21, 2016

Appl. No.:

15/357435

Inventors:

- Norman OK, US
Kenneth W. Jackson - Edmond OK, US
Kyung N. Lee - Oklahoma City OK, US
Victoria J. Christiansen - Oklahoma City OK, US

International Classification:

C07K 5/062
C07K 5/11
C07K 5/083
C07K 7/02
C07K 5/02

Abstract:

The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α-antiplasmin and abnormal cell proliferation. The presently disclosed inventive concept(s) also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed inventive concept(s) further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma α-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.

US Patent:

20150141660, May 21, 2015

Filed:

Jan 8, 2015

Appl. No.:

14/592178

Inventors:

- Norman OK, US
Kenneth W. Jackson - Edmond OK, US
Kyung N. Lee - Oklahoma City OK, US
Victoria J. Christiansen - Oklahoma City OK, US

International Classification:

C07K 5/02

US Classification:

548405

Abstract:

The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma α-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.

US Patent:

20150119330, Apr 30, 2015

Filed:

May 3, 2013

Appl. No.:

14/398886

Inventors:

- Norman OK, US
Kenneth W. Jackson - Edmond OK, US
Victoria J. Christiansen - Oklahoma City OK, US

International Classification:

C07K 7/06
C07K 5/11
C07K 5/09

US Classification:

514 133, 530331, 530330, 514 219, 530329, 514 218, 435184

Abstract:

Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.